Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4DHF

Structure of Aurora A mutant bound to Biogenidec cpd 15

Summary for 4DHF
Entry DOI10.2210/pdb4dhf/pdb
Related3R21 3R22
DescriptorAurora kinase A, 7-cyclopentyl-2-({1-methyl-5-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-3-yl}amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, PHOSPHATE ION, ... (4 entities in total)
Functional Keywordsser/thr kinase mitotic kinase pyrazolopyrimidine, phosphorylation, tpx2, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (human)
Cellular locationCytoplasm, cytoskeleton, centrosome: O14965
Total number of polymer chains2
Total formula weight63833.50
Authors
Silvian, L.,Marcotte, D.J. (deposition date: 2012-01-27, release date: 2012-07-18, Last modification date: 2024-02-28)
Primary citationLe Brazidec, J.Y.,Pasis, A.,Tam, B.,Boykin, C.,Wang, D.,Marcotte, D.J.,Claassen, G.,Chong, J.H.,Chao, J.,Fan, J.,Nguyen, K.,Silvian, L.,Ling, L.,Zhang, L.,Choi, M.,Teng, M.,Pathan, N.,Zhao, S.,Li, T.,Taveras, A.
Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
Bioorg.Med.Chem.Lett., 22:4033-4037, 2012
Cited by
PubMed Abstract: This Letter reports the optimization of a pyrrolopyrimidine series as dual inhibitors of Aurora A/B kinases. This series derived from a pyrazolopyrimidine series previously reported as inhibitors of aurora kinases and CDKs. In an effort to improve the selectivity of this chemotype, we switched to the pyrrolopyrimidine core which allowed functionalization on C-2. In addition, the modeling rationale was based on superimposing the structures of Aurora-A kinase and CDK2 which revealed enough differences leading to a path for selectivity improvement. The synthesis of the new series of pyrrolopyrimidine analogs relied on the development of a different route for the two key intermediates 7 and 19 which led to analogs with both tunable activity against CDK1 and maintained cell potency.
PubMed: 22607669
DOI: 10.1016/j.bmcl.2012.04.085
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.8 Å)
Structure validation

239492

数据于2025-07-30公开中

PDB statisticsPDBj update infoContact PDBjnumon